Loxo Oncology at Lilly has agreed to partner with Merus to develop up to three CD3-engaging T-cell re-directing bispecific antibody therapies based on its Biclonics® platform. The deal, which is worth up to US$1.7 B, comes a year after Loxo Oncology at Lilly was formed from the combination of the Lilly Research Laboratories oncology business and Loxo Oncology, as part of Lilly’s strategy to revamp its cancer business.